斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

wÖrwag pharma gmbh & co.kg, nemecko - kyanokobalamín - 86 - vitamina, vitagena

斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - kyselina ibandrónová - 87 - varia i

斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - kyselina ibandrónová - 87 - varia i

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatitída c, chronická - antivirotiká na systémové použitie - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 a 5.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatitída c, chronická - antivirotiká na systémové použitie - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 a 5. pre vírusom hepatitídy c (hcv) genotyp-konkrétne aktivity pozri časť 4. 4 a 5.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir - hepatitída c, chronická - antivirotiká na systémové použitie - sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 a 5. pre vírusom hepatitídy c (hcv) genotyp špecifické činnosti, pozri časť 4. 4 a 5. sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 a 5. pre vírusom hepatitídy c (hcv) genotyp špecifické činnosti, pozri časť 4. 4 a 5.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitída c, chronická - antivirotiká na systémové použitie - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitída c, chronická - antivirotiká na systémové použitie - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (pozri časť 4. 2, 4. 4 a 5.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

theramex ireland limited - teriparatid - osteoporóza - homeostáza vápnika - livogiva is indicated in adults. liečba osteoporózy u postmenopauzálnych žien a u mužov so zvýšeným rizikom zlomeniny. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. liečba osteoporózy spojené s trvalým systémové glukokortikoidy terapie u žien a mužov, zvýšené riziko zlomeniny.